PLURISTEM THERAPEUTICS (NASD: PSTI)
"Up 107.90% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/PSTI.php

Pluristem Therapeutics, Inc. engages in the research and development of the mesenchymal and stem cell production technology, and the commercialization of cell therapy products. The company is developing a platform designed to create a functional stem cell production system that can treat severe blood, cardiovascular, autoimmune, and other disorders. It develops PluriX Bioreactor System, which is designed to be a system of stromal cell cultures and substrates that creates an artificial physiological environment where mesenchymal stem cells can grow and reproduce outside of the human body without any use of exogenous biologics or pharmacologicals. The company's principal product, PLX-I is intended to resolve the shortfall of matched tissue for bone marrow transplantation by improving the engraftment of hematopoietic stem cells contained umbilical cord blood. Pluristem's products are derived from mesenchymal stem cells obtained from the placenta and expanded in its proprietary PluriX 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines, or other exogenous materials. The company was founded in 2001 as A.I. Software, Inc. and changed its name to Pluristem Life Systems, Inc. in 2003. Further, it changed its name to Pluristem Therapeutics, Inc. in November 2007. Pluristem Therapeutics is based in Haifa, Israel.

PSTI News:

April 7 - Pluristem's Second Pre-Clinical Study in Ischemic Stroke Shows Statistically Significant Advantages in Functional and Anatomical Recovery

Pluristem Therapeutics Inc. (NASD: PSTI) (DAX: PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced that the results from Fraunhofer Institute’s additional pre-clinical study utilizing the company’s proprietary PLacental eXpanded (PLX) cells in treating ischemic stroke showed statistical significance utilizing functional as well as anatomical endpoints. PLX cells are mesenchymal stromal cells (MSCs) obtained from the placenta and expanded using Pluristem’s proprietary 3D PluriX™ technology.

Fraunhofer Institute’s scientists systemically injected PLX cells into spontaneously hypertensive rats that had undergone middle cerebral artery occlusion, a commonly accepted ischemic stroke model. The functional endpoints of improvement in beam walking and neurological severity score and the anatomical endpoint of reduction in infarct size reached statistical significance versus controls.

Zami Aberman, Pluristem’s president and CEO said: “We are very excited about the results and believe that utilizing our PLX product may successfully treat millions of ischemic stroke patients and lead to a multi-billion dollar market. This independent study, together with the previously announced favorable pre-clinical results of PLX cells to treat limb ischemia and blood cancer, give us a robust pipe line for developing new therapeutic products.”

The trial was conducted under the supervision of Professor Frank Emmrich, Head of the Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany, a branch of the Fraunhofer Society.

Prof. Frank Emmrich stated, "PLX cells possibly show potential to become a new treatment for the functional recovery from a stroke. The data show that a double injection of PLX cells at two different time points significantly improve the functional recovery and reduce of size of the lesion compared to the control. However, these preliminary findings have to be confirmed and the running experimental series have to be completed before a final statement can be made. Additional optimization surrounding the administration of PLX cells will be required to supply clear evidence that PLX cells may help patients with ischemic stroke.”

ABOUT ISCHEMIC STROKE

Ischemic stroke accounts for approximately 90% of all stroke cases and is caused when an artery to the brain becomes blocked causing a sudden disruption of blood flow. Current estimates suggest ischemic stroke affects approximately 2 million patients annually worldwide with a large percentage dying or becoming permanently disabled. Industry leaders have estimated the potential market for treating ischemic stroke to be approximately $4 billion.

ABOUT FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY

The Fraunhofer Institute for Immunology and Cell Therapy (IZI) founded in April 2005 is member of the Fraunhofer Life Sciences Alliance. Its objective being to find solutions to specific problems at the interfaces between medicine, life sciences and engineering for partners active in medicine-related industries and businesses. The Institute’s core competencies are to be found in regenerative medicine, or more precisely in cell-therapeutic methods of regenerating non-functioning tissue and organs through to the biological substitution with tissue cultivated in vitro (tissue engineering). In order for the living organism to accept the tissues without any difficulty, it is necessary to study cellular and immunological defense and control mechanisms and take these into account during process and product development. These core competencies entail a multiplicity of tasks to be solved by new products and processes. The Institute works especially closely with hospital institutions, performing quality tests and clinical studies on their behalf. Additionally it also provides assistance in obtaining manufacturing licenses and certifications.

EXPERT GROUP INCORPORATED (OTC: EXPT)
"Up 130.00% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/EXPT.php

Expert Group, Inc. is a diversified financial services company which markets a variety of financial products and services through Expert Financing, Expert Group Title Services, Expert Credit Fix USA. Expert is licensed by the department of Financial Regulations and a member of FAMB, and since inception, Expert has originated over $50 million in origination. The Company offers a stock option plan to its loan officers, brokers, title agents, and processors.

EXPT News:

April 2 - Expert Group Announces March 2008 Financial Figures

Expert Group, Inc. (OTC: EXPT) announced that the Company for the month of March originated $1.3 million in loans, bringing a $50,000 net profit to the Company. This figure also does not reflect the recent addition of ten new loan officers during the month of March who were added in order to capitalize on Expert Group's building momentum and to capture additional revenues.

According to a company spokesperson for Expert Group, "We are understandably pleased to be able to announce the realization of net profitability. However, as far as we are concerned, this is just a preview of our anticipated success. With the rapid growth of our Broker Network and the recently announced launch of Expert Credit Fix USA, we are greatly enhancing our abilities to serve a broader range of clients more effectively, and thereby substantially increasing the potential for greater revenue generation. We feel that we are well on pace to reach our projections of $1 million in net profits for 2008, and based on our latest achievements, we are extremely optimistic about our prospects through 2008 and beyond."

For the month of April, the Company will run a national special. For anyone that is considering buying a home with Expert Financing, but is faced with difficulties as a result of negative credit issues, Expert Financing will reimburse any of its clients who take advantage of the credit repair services of Expert Credit Fix USA. In other words, any client who closes a loan with Expert Financing and who utilizes the credit repair services of Expert Credit Fix USA, Expert Financing will reimburse the cost of those credit repair services.

For more information, check out the extensive list of products and services at www.expertfinancing.net and www.expertcreditfixusa.com, or call toll free 1-877-949-3700 to speak to a Loan Expert.

FINELINE HOLDINGS INCORPORATED (OTC: FNLH)
"Up 65.00% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/FNLH.php

Fineline Holdings, Inc. engages in the creation and development of cartoon characters for licensing and merchandising to corporations. The company’s products include cartoons and cartoon groups. It also maintains an e-commerce Internet signature store that sells FineLine branded apparel and products, including designer shirts, women Jersey tops and dresses, and T-shirts. As of September 30, 2004, the company had 147 trademarked and copyrighted cartoons. It markets its products in the United States, Canada, Mexico, Europe, Asia, and South America. The company was formed in 1988 as Fineline Properties, Inc. and changed its name to Fineline Properties.Com, Inc. in 1998. Further, the name was changed to Fineline Holdings, Inc. in January 2005. Fineline Holdings is based in Kent, Ohio.

FNLH News:

April 7 - Fineline Holdings Inc. Management Adds Merchant Banking Advisory Services to Its Current Business Interests

In an effort to continue to build shareholder equity, Fineline Holdings, Inc. (OTC: FNLH) will be expanding its reach to provide merchant bank consulting, and corporate finance advisory services to other microcap issuers. These micro-cap opportunities are typically either in operational or financial difficulty and may need corporate restructuring, merger & acquisition advisory services, and bridge financing. They are typically facing market awareness issues and an inability to attract corporate financing and require the help of serious, experienced managers to restructure and turnaround public company operations in an expedient manner.

Fineline Holdings, Inc. will be generally compensated with a combination of cash payments on a case-by-case basis, and outright grants of equity in the form of common stock and warrants for purchasing the common stock of the public company. We believe this compensation plan aligns our interests with the client company's shareholders because our ultimate compensation is maximized by successfully increasing shareholder equity. Naturally our own intent is also to increase shareholder equity in our company as we crystallize our services. A new website is being created to define our past and present business interests.

REBUILDER MEDICAL TECHNOLOGIES (OTC: RBRM)
"Up 43.33% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/RBRM.php

ReBuilder Medical Technologies, Inc. has been successfully inventing, developing, manufacturing, and distributing medical devices for five years via the internet. The company is now expanding its marketing to reach beyond the internet to include physician's offices and late night TV infomercials. RBRM is about to roll out its new line of personal hygiene products for those who suffer with diabetes as well. The company is also performing R&D on two new devices, one to make veins "pop out" to make it easier for nurses to draw blood samples and another to detect allergies electronically. ReBuilder Medical Technologies is headed by David B. Phillips, Ph.D., who has a successful 30 year history of inventing medical devices that include the first infrared ear thermometer (FirsTemp), the GST System for Breast Cancer Detection, and other medical innovations. Sales for 2007 have doubled each month over the same period in 2006. Current sales volume is at the rate of $3 million annually. ReBuilder Medical Inc. is a multi-disciplinary medical device company specializing in neuropathy, molluscum and diabetes.

RBRM News:

April 7 - ReBuilder Medical Technologies, Inc. Seeks Listing on NASDAQ

ReBuilder Medical Technologies, Inc. (OTC: RBRM), President/CEO, David B. Phillips, Ph.D, announced that the corporation is ready to grow into one of the larger, more efficient, and transparent public equity markets.

"We have been a publicly held company for a year and have experienced the limitations of being listed only on the Pink Sheets with a large number of shares and a low price per share" said Dr. Phillips. "We have maintained a fully reporting status on Pink Sheets, and are prepared to meet the requirements that the NASDAQ and other markets require. Recent publicity surrounding these small equity markets indicates that without changing the percentage of ownership for our shareholders, we can add value by ensuring our price per share is in line with the larger markets. We do not anticipate offering any new equities, nor do we anticipate using any debt instruments. We are comfortable being a cash company with no receivables and no debt."

"Our next focus will be to evaluate the equity structure of our company to enable us to reach bigger equity markets that can better reflect our credibility. We are reviewing the relevant data and will keep our current investors apprised of our progress," states Dr. Phillips.

For more information, visit www.rebuildermedical.com and www.molluscum.com.

TRANSDEL PHARMACEUTICALS INCORPORATED (OTCBB: TDLP)
"Up 54.55% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/TDLP.php

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of non-invasive topically delivered medications. The company's lead topical drug candidate, Ketotransdel, utilizes its proprietary Transdel cream formulation to facilitate the passage of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the epidermis and into underlying tissues. Ketotransdel provides an alternative to the oral administration of cyclooxygenase-2 selective NSAIDs (COX-2 inhibitors) and non-selective NSAIDs. It has completed a Phase 1/2 trial for treating soft tissue pain and soreness in a delayed onset muscle soreness model with Ketotransdel. Transdel Pharmaceuticals also investigates other drug candidates and treatments for transdermal delivery using Transdel technology, including anesthetics, human hormone replacement, and anti-nausea medications. The company was founded in 1998 and is headquartered in La Jolla, California.

TDLP News:

April 7 - Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) announced that, based on the U.S. Food and Drug Administration's ("FDA") review of its Phase 3 submission, the company can initiate its Phase 3 clinical program for its novel topical cream based non-steroidal anti-inflammatory drug ("NSAID"), Ketotransdel(TM). Transdel Pharmaceuticals is a specialty pharmaceutical company pursuing the development and commercialization of non-invasive topically administered medications.

Dr. Juliet Singh, President and Chief Executive Officer of Transdel Pharmaceuticals, stated, "I am pleased to announce that the FDA has reviewed our February 7, 2008 FDA submission and has stated that it is safe to proceed with the Phase 3 program. The FDA also noted that there are no clinical hold issues and provided comments regarding the registration requirements of our lead drug. We will continue our discussions with the FDA regarding the final product approval requirements." Dr. Singh continued, "Advancing into Phase 3 clinical studies for Ketotransdel marks a significant milestone for the company. Our dedicated and committed team is focused on successfully advancing our topical drug to FDA approval."

Based on industry estimates, the market for NSAIDs and Cox-2 inhibitors exceeds $6 billion per year; more than 30 million people worldwide use NSAIDs daily. Due to the recognition of known risks associated with orally administered NSAIDs, including cardiovascular, gastrointestinal and other medical complications, and the decline in the use of Cox-2 inhibitors because of safety concerns, Transdel believes that there is a significant demand for topical pain management products such as Ketotransdel. Moreover, the company expects that Ketotransdel, if approved by the FDA, could become the first topical NSAID cream product in the United States for acute pain management. The drug could address a significant unmet medical need for patients with medical conditions and those patients seeking safer alternatives to the standard pain management approaches.

In the second quarter of 2008, the company intends to initiate the randomized, double-blind, placebo controlled Phase 3 program to evaluate the efficacy and safety of Ketotransdel in acute pain care management. The company also stated that in the near term it will be announcing organizational changes as the company transitions into late stage clinical phase.

ENZYME ENVIRONMENTAL (OTC: EESO)
"Up 52.94% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/EESO.php

Enzyme Consultants Organization (ECO) is a U.S. based manufacturer of industrial and agricultural enzyme products. All manufacturing, testing, and formulating are conducted in its manufacturing plant, located in Fort Wayne, Indiana. ECO strives to become a leader in ecological friendly or “Green Products” targeting the industrial and agricultural markets. It is our goal to have the best performing products on the market in each industry. Developing a growing and satisfied customer base is our number one marketing strategy.

EESO News:

April 7 - Enzyme Environmental Solutions Announces CEO Interview

Enzyme Environmental Solutions Inc. (OTC: EESO) announced its first CEO video interview has been posted on YouTube at:

www.youtube.com/watch?v=aGUBSqLF-Pg.

The company plans to use this method of interview on a regular reoccurring basis to keep shareholders updated and in touch with the company's progress.

CEO Jared Hochstedler further stated, "I want to really tell everyone how much I appreciate all the support that has been given. My promise to all shareholders is to do my best to build shareholder value and to be as transparent as possible."

The company would also like to confirm that as of April 7, 2008 the outstanding share count remains at 223,716,398 commons shares issued and outstanding.